5-[(2-bromophenoxy)methyl]-4,5-dihydro-oxazol-2-ylamine | 359715-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[(2-bromophenoxy)methyl]-4,5-dihydro-oxazol-2-ylamine
• 英文别名: S-23515；2-Oxazolamine, 5-[(2-bromophenoxy)methyl]-4,5-dihydro-；5-[(2-bromophenoxy)methyl]-4,5-dihydro-1,3-oxazol-2-amine
• CAS: 359715-57-4
• 化学式: C₁₀H₁₁BrN₂O₂
• 分子量: 271.114
• InChiKey: GUVAJKCAUCHQID-UHFFFAOYSA-N

物化性质

• 沸点：
  373.0±38.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS
  申请人：CURRIE Mark G.

  公开号：US20090054450A1

  公开（公告）日：2009-02-26

  Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.

  本文披露了一种用于治疗或预防与脂质代谢相关的多种疾病和病症的新型组合物和方法。该方法通常包括向需要治疗的患者施用一种药物组合物，该组合物包括一种或多种纤维酸或他汀类衍生物组合物，单独或与一种或多种脂质调节剂和/或PDE抑制剂组合使用的治疗有效量。
• Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
  申请人：Baum Dominique

  公开号：US20050143435A1

  公开（公告）日：2005-06-30

  Parmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

  由选择性咪唑啉受体激动剂和血管紧张素 II 受体阻滞剂组成的药物组合物，特别是由莫索尼定和甲磺酸依普沙坦组成的药物组合物，以及使用此类组合物治疗高血压，尤其是治疗患有 II 型糖尿病或易患 II 型糖尿病的高血压患者。
• Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins
  申请人：Rupp Heinz

  公开号：US20050165080A1

  公开（公告）日：2005-07-28

  The use of selective imidazoline receptor agonists, such as moxonidine, rilmenidine, LNP-509, S-23515, PMS-812, PMS-847 and BU-98008, and their physiologically compatible acid addition salts in pharmaceutical preparations for the treatment and/or inhibition of functional disorders and/or diseases in larger mammals or humans which require inhibition or reduction of the activity of proteins which regulate the intracellular pH value and which belong to the superfamily of bicarbonate transporters, in particular the treatment or inhibition of clinical conditions of bones which are caused by an undesirable amount of bone resorption, such as osteoporosis; of diseases of the gastrointestinal tract, such as gastric ulcers; and of neuronal and/or neuropsychiatric diseases associated with a pathologically altered (especially increased) neuronal activity, such as depression, Alzheimer's disease, eating disorders and schizophrenia.

  在药物制剂中使用选择性咪唑啉受体激动剂，如莫索尼定、利美尼定、LNP-509、S-23515、PMS-812、PMS-847 和 BU-98008，以及它们与生理相容的酸加成盐，用于治疗和/或抑制大型哺乳动物或人类的功能紊乱和/或疾病，这些疾病需要抑制或降低调节细胞内 pH 值的蛋白质的活性，这些蛋白质属于碳酸氢盐转运体超家族、特别是治疗或抑制因骨吸收量过大而引起的骨骼临床症状，如骨质疏松症；胃肠道疾病，如胃溃疡；以及与神经元活性病理性改变（尤其是增加）有关的神经元和/或神经精神疾病，如抑郁症、阿尔茨海默病、饮食失调症和精神分裂症。
• ARZNEIMITTEL ZUR BEHANDLUNG VON EINE INHIBITION ODER AKTIVITÄTSVERMINDERUNG VON PH-WERT-REGULIERENDEN BIKARBONAT-TRANSPORTER-PROTEINEN ERFORDERNDEN ERKRANGUNGEN
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1517688A2

  公开（公告）日：2005-03-30
• PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1673107A2

  公开（公告）日：2006-06-28